StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Saturday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of Enzo Biochem stock opened at $1.12 on Friday. Enzo Biochem has a 12-month low of $0.99 and a 12-month high of $1.50. The company’s 50-day moving average price is $1.12 and its 200-day moving average price is $1.13.

Institutional Investors Weigh In On Enzo Biochem

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wittenberg Investment Management Inc. bought a new position in shares of Enzo Biochem in the fourth quarter worth approximately $95,000. Renaissance Technologies LLC lifted its position in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the period. Finally, XTX Topco Ltd lifted its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the period. 36.90% of the stock is owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.